• Briganix 180 mg (Brigatinib): ALK Positive Lung Cancer Quick View
    • Briganix 180 mg (Brigatinib): ALK Positive Lung Cancer Quick View
    • Briganix 180 mg (Brigatinib): ALK Positive Lung Cancer

    • Briganix 180 mg (Brigatinib) is a cutting-edge oral medication designed to treat ALK-positive non-small cell lung cancer (NSCLC) in adults. Brigatinib is a next-generation tyrosine kinase inhibitor (TKI) that targets the abnormal anaplastic lymphoma kinase (ALK) gene mutation, a key driver of cancer cell growth in ALK-positive lung cancer. This medication is particularly effective for patients whose cancer has progressed…
    • Read more
  • Briganix 90 mg (Brigatinib): ALK Positive Lung Cancer Quick View
    • Briganix 90 mg (Brigatinib): ALK Positive Lung Cancer Quick View
    • Briganix 90 mg (Brigatinib): ALK Positive Lung Cancer

    • Briganix 90 mg (Brigatinib) is an advanced oral medication specifically designed for the treatment of ALK-positive non-small cell lung cancer (NSCLC) in adults. Brigatinib is a next-generation tyrosine kinase inhibitor (TKI) that targets the abnormal anaplastic lymphoma kinase (ALK) gene mutation, a key driver of cancer cell growth in some forms of lung cancer. Briganix 90 mg is especially effective…
    • Read more
  • Crizocent 250mg: ALK Positive and ROS1 Lung Cancer Quick View
    • Crizocent 250mg: ALK Positive and ROS1 Lung Cancer Quick View
    • Crizocent 250mg: ALK Positive and ROS1 Lung Cancer

    • Crizocent 250mg (Crizotinib) is a highly effective targeted therapy specifically designed to treat advanced non-small cell lung cancer (NSCLC) that is ALK-positive (anaplastic lymphoma kinase) or ROS1-positive. This innovative medication works by blocking the activity of proteins (ALK and ROS1) that promote cancer cell growth, making it an essential treatment for patients with these specific genetic mutations. Crizocent is trusted…
    • Read more
  • Lorlatinib(Lorbrexen 100mg): ALK Positive Lung Cancer Quick View
    • Lorlatinib(Lorbrexen 100mg): ALK Positive Lung Cancer Quick View
    • ,
    • Lorlatinib(Lorbrexen 100mg): ALK Positive Lung Cancer

    • Lorbrexen (Lorlatinib 100mg) is an innovative cancer therapy specifically designed to treat non-small cell lung cancer (NSCLC) that is positive for ALK (anaplastic lymphoma kinase) mutations. This targeted therapy is highly effective in managing advanced stages of ALK-positive NSCLC, especially in patients whose cancer has progressed despite prior treatment with other ALK inhibitors. Lorbrexen works by blocking the activity of…
    • Read more
  • Rizonib 250 mg (Crizotinib): ALK Positive Lung Cancer Quick View
    • Rizonib 250 mg (Crizotinib): ALK Positive Lung Cancer Quick View
    • Rizonib 250 mg (Crizotinib): ALK Positive Lung Cancer

    • Rizonib 250 mg (Crizotinib) is an advanced oral medication used to treat non-small cell lung cancer (NSCLC) that is ALK-positive (anaplastic lymphoma kinase-positive) or ROS1-positive. Crizotinib, the active ingredient in Rizonib, is a targeted therapy that works by inhibiting the abnormal proteins responsible for driving the growth of cancer cells. This powerful treatment offers hope for patients with advanced or…
    • Read more